GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mochida Pharmaceutical Co Ltd (TSE:4534) » Definitions » Debt-to-EBITDA

Mochida Pharmaceutical Co (TSE:4534) Debt-to-EBITDA : 0.00 (As of Dec. 2023)


View and export this data going back to 1963. Start your Free Trial

What is Mochida Pharmaceutical Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Mochida Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円0 Mil. Mochida Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円0 Mil. Mochida Pharmaceutical Co's annualized EBITDA for the quarter that ended in Dec. 2023 was 円7,980 Mil. Mochida Pharmaceutical Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Mochida Pharmaceutical Co's Debt-to-EBITDA or its related term are showing as below:

During the past 13 years, the highest Debt-to-EBITDA Ratio of Mochida Pharmaceutical Co was 0.04. The lowest was 0.00. And the median was 0.03.

TSE:4534's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.69
* Ranked among companies with meaningful Debt-to-EBITDA only.

Mochida Pharmaceutical Co Debt-to-EBITDA Historical Data

The historical data trend for Mochida Pharmaceutical Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mochida Pharmaceutical Co Debt-to-EBITDA Chart

Mochida Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Mochida Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Mochida Pharmaceutical Co's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Mochida Pharmaceutical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mochida Pharmaceutical Co's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mochida Pharmaceutical Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Mochida Pharmaceutical Co's Debt-to-EBITDA falls into.



Mochida Pharmaceutical Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Mochida Pharmaceutical Co's Debt-to-EBITDA for the fiscal year that ended in Mar. 2024 is calculated as

Mochida Pharmaceutical Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Mochida Pharmaceutical Co  (TSE:4534) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Mochida Pharmaceutical Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Mochida Pharmaceutical Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Mochida Pharmaceutical Co (TSE:4534) Business Description

Traded in Other Exchanges
N/A
Address
1-1 Ichigayahonmuracho, Shinjuku-ku, Tokyo, JPN, 162-0845
Mochida Pharmaceutical Co Ltd is a major drug manufacturing company that operates in the field of medical care through its pharmaceuticals, healthcare products, and medical equipment businesses. The company's pharmaceuticals business aims to develop and market a broad spectrum of innovative new drugs. One of Mochida's main objectives is to maximize the business performance of its drugs after they are developed and released. The company also creates skin care products for the general public, and these are supplied through pharmacies, drugstores, and mail-order sales.

Mochida Pharmaceutical Co (TSE:4534) Headlines

No Headlines